Pilot trial of albuterol in spinal muscular atrophy
- 27 August 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 59 (4) , 609-610
- https://doi.org/10.1212/wnl.59.4.609
Abstract
The aim of this pilot study was to evaluate the effect of albuterol in children with spinal muscular atrophy (SMA). Thirteen patients (five with SMA II and eight with SMA III) were given oral albuterol for 6 months. There was a significant increase in myometry, forced vital capacity, and lean body mass between the baseline and the 6-month assessments (p < 0.05). Albuterol may have a beneficial effect in patients with SMA without causing any significant adverse effects. Larger randomized, placebo-controlled trials are needed to confirm this observation.Keywords
This publication has 6 references indexed in Scilit:
- Reference values of maximum isometric muscle force obtained in 270 children aged 4–16 years by hand-held dynamometryPublished by Elsevier ,2001
- Beneficial versus adverse effects of long‐term use of clenbuterol in mdx miceMuscle & Nerve, 1995
- Natural History in Proximal Spinal Muscular AtrophyArchives of Neurology, 1995
- Increased muscle strength in paralyzed patients after spinal cord injury: Effect of beta-2 adrenergic agonistArchives of Physical Medicine and Rehabilitation, 1995
- Clenbuterol, a β-Adrenoceptor Agonist, Increases Relative Muscle Strength in Orthopaedic PatientsClinical Science, 1993
- Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young menClinical Science, 1992